To further determine whether the endogenous antigenic peptides delivered by CBP-12 also induce immune responses in the anti-PD-1-resistant tumor B16 model, we synthesized a CBP-12-gp100 conjugated peptide vaccine (Figure 3A), in which the antigenic peptide (glycoprotein 100) was selected from melanocyte lineage-specific endogenous antigens 28. The gene discussed is PMEL; the disease is neoplasm.